antagonistic drugs

In the past few years, a new class of drugs represented by PD-1 inhibitors has sprung up in the field of cancer treatment, attracting the attention of biomedical workers. Creative Biolabs is aware of the potential of these drugs and has established an excellent research team to create a high level of antagonist antibody development and detection platform. Our antagonist antibody therapy service technology platform is dedicated to providing high-quality services to our customers and working hard to turn the antibodies developed by our customers into usable pharmaceutical products.
Introduction to Antagonistic Antibody
Immune cells are strictly regulated by co-inhibition and co-stimulation receptors, which activate immune cells to function after binding to the ligand, while co-inhibition receptors inhibit signal transmission to prevent immune cells from attacking other normal cells. Tumor cells can avoid being targeted by immune cells by controlling these receptors, called immune checkpoints. In contrast, modern medical techniques have developed antagonist or agonist antibody drugs that activate or suppress the activity of immune receptors. These drugs specifically bind to various immune checkpoints and regulate the activity of immune cells. At present, antibody drugs related to antagonists have shown good effects in the treatment of many diseases including cancer, and many drugs are still in the development stage. It is foreseeable that such drugs will help us maximize the function of the body's own immune system in the defense of diseases in the future.
Learn more about antagonistic drugs: https://www.creative-biolabs.com/antagonistic-antibody-therapy.html